Company news

Ningbo Menovo Pharmaceutical Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on the Subsidiary Re-certified as High-tech Enterprise

January 22, 2026

Notice on Convening the 1st Extraordinary General Meeting in 2026

January 16, 2026

Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Adempas Riociguat Tablets

January 12, 2026

Indicative Announcement on the Expected Meeting of Conditions for Downward Correction of Conversion Price for "Menovo Convertible Bonds"

January 9, 2026

in 2026

January 7, 2026

Announcement on Self-exercise Results of Initially Granted Portion in the 3rd Exercise Period of the 2021 Stock Option Incentive and Restricted Stock Plan and Share Changes

December 30, 2025

Announcement on Resolutions of the 22nd Meeting of the 5th Board of Directors

December 24, 2025

Announcement on CDE’s Technical Review of the Drug Substance Atorvastatin Calcium by the Holding Subsidiary

December 18, 2025

Announcement on Resolutions of the 21st Meeting of the 5th Board of Directors

December 15, 2025

Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Febuxostat Tablets

December 10, 2025

Announcement on Resolutions of the 20th Meeting of the 5th Board of Directors

December 3, 2025

Announcement on Self-exercise Results of Reserved and Granted Portion in the 2nd Exercise Period of the 2021 Stock Option Incentive and Restricted Stock Plan and Share Changes

November 25, 2025

Announcement on Convening the Q3 2025 Performance Briefing

November 19, 2025

Announcement on Not Revising Downward Conversion Price of "Menovo Convertible Bonds"

November 12, 2025

Announcement on Resolutions of the 18th Meeting of the 5th Board of Directors

October 27, 2025

Announcement on Wholly-owned Subsidiary Obtaining Drug Registration Certificate for Irbesartan and Hydrochlorothiazide Tablets

October 20, 2025

Announcement on Resolutions of the 17th Meeting of the 5th Board of Directors

October 17, 2025

← Newer news releases